Skip to main content

Advertisement

SpringerLink
Log in

FcR may function as a progression factor of nonlymphoid tumors

  • FcR and Tumor Progression
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Tumor progression is a multistep process involving genetic and epigenetic changes in a transformed clone. Some of these changes may be induced by host factors which may also select for transformed cellular variants with a high ability to survive and propagate. In this article we review studies showing that receptors for the Fc portion of IgG may be expressed on cells from human or animal tumors of nonlymphoid origin. We also review data demonstrating that at least with respect to cells transformed in vitro with Polyoma virus, transformation per se is not sufficient for the induction of Fc receptor expression. We also summarize preliminary data showing that Fc receptor expression is causally involved in conferring a high malignancy phenotype upon transformed cells. Possible mechanisms to explain these observations are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weinberg RA: Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713–3721.

    PubMed  CAS  Google Scholar 

  2. Farber E, Cameron R: The sequential analysis of cancer development. Adv Cancer Res 1980;31:125–226.

    PubMed  CAS  Google Scholar 

  3. Heppner GH: Tumor heterogeneity. Cancer Res 1984;44:2259–2265.

    PubMed  CAS  Google Scholar 

  4. Nicolson GL: Generation of phenotypic diversity and progression in metastatic tumors. Cancer Metastasis Rev 1984;3:25–42.

    PubMed  CAS  Google Scholar 

  5. Kerbel RS, Frost P, Litepolo R, Carlow DA, Elliott BF: Possible epigenetic mechanisms of tumor progression: Induction of high frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol 1984;3(suppl): 87–97.

    CAS  Google Scholar 

  6. Klein G, Klein E: Conditioned tumorigenicity of activated oncogenes. Cancer Res 1986;46:3211–3224.

    PubMed  CAS  Google Scholar 

  7. Bishop JM: The molecular genetics of cancer. Science 1987;235:305–311.

    PubMed  CAS  Google Scholar 

  8. Frost P, Kerbel RS, Hunt B, Man S, Pathak S: Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2′-deoxy-5-azacytidine or hydroxyurea: Implications for the mechanisms of tumor progression. Cancer Res 1987;47:2690–2695.

    PubMed  CAS  Google Scholar 

  9. Holliday R: The inheritance of epigenetic defects. Science 1987;238: 163–169.

    PubMed  CAS  Google Scholar 

  10. Nicolson GL: Tumor cell instability, diversification and progression of the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 1987;47:1473–1487.

    PubMed  CAS  Google Scholar 

  11. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.

    PubMed  CAS  Google Scholar 

  12. Halachmi E, Witz IP: Differential tumorigenicity of 3T3 cells transformed in vitro with polyoma virus and in-vivo selection for high tumorigenicity. Cancer Res 1989;49: 2383–2389.

    PubMed  CAS  Google Scholar 

  13. Nowell PC: The clonal evolution of tumor cell populations. Science 1976;194:23–28.

    PubMed  CAS  Google Scholar 

  14. Nowell PC: Mechanisms of tumor progression. Cancer Res 1986;46: 2203–2207.

    PubMed  CAS  Google Scholar 

  15. Clifone M, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 1981;78:6249–6252.

    Google Scholar 

  16. Wolman SR: Karyotypic progression in human tumors. Cancer Metastasis Rev 1983;2:257–293.

    PubMed  CAS  Google Scholar 

  17. Bosslet K, Schirrmacher V: High frequency generation of new immunoresistant tumor variants during metastasis of a clonal murine tumor line (ESb). Int J Cancer 1982;29: 195–202.

    PubMed  CAS  Google Scholar 

  18. Chow DA: Variant generation and selection: An in-vitro model of tumor progression. Int J Cancer 1984; 33:541–545.

    PubMed  CAS  Google Scholar 

  19. Ehrlich R, Efrati M, Malatzky E, Shohat L, Bar-Eyal A, Witz IP: Natural host defense during oncogenesis, NK activity and dimethylbenzanthracene carcinogenesis. Int J Cancer 1983;31:67–73.

    PubMed  CAS  Google Scholar 

  20. Witz IP, Yaakubovicz M, Gelernter I, Hochberg Y, Anavi R, Ran M: Studies on the level of natural antibodies reactive with various tumor cells during urethan carcinogenesis in BALB/c mice. Immunobiology 1984;166:131–145.

    PubMed  CAS  Google Scholar 

  21. Yron I, Schikler M, Fisch B, Pinkas H, Ovadia J, Witz IP: The immune system during the precancer and the early cancer period. IL-2 production by PBL from postmenopausal women with and without endometrial carcinoma. Int J Cancer 1986; 38:331–338.

    PubMed  CAS  Google Scholar 

  22. Ehrlich R, Gonen B, Sahar E, Efrati M, Smorodinsky N, Shohat L, Sagi O, Witz IP: The immunity system during the precancer period. Marker and function analysis of NK and alloreactive T cells during early stages of DMBA carcinogenesis. Nat Immun Cell Growth Regul 1986;5: 305–316.

    PubMed  CAS  Google Scholar 

  23. Witz IP, Agassy-Cahalon L: Do naturally occurring antibodies play a role in the progression and proliferation of tumor cells?. Int Rev Immunol 1987;3:133–145.

    Google Scholar 

  24. Gonen B, Ran M, Wreshner D, Cahalon L, Anavi R, Shlomo Y, Witz IP: Some immunological properties of high and low tumorigenic cellular variants of C-H-ras transformed 3T3 cells. Nat Immun Cell Growth Regul 1988;7:144–154.

    PubMed  CAS  Google Scholar 

  25. Sutherland RM: Cell and Environment interactions in tumor microregions: The multicell spheroid model. Science 1988;240:177–184.

    PubMed  CAS  Google Scholar 

  26. Liotta LA: Tumor invasion and metastasis: Role of the extracellular matrix. Cancer Res 1986;46:1–7.

    Article  PubMed  CAS  Google Scholar 

  27. Price JE, Naito S, Fidler IJ: The role of organ microenvironment in the selective process of metastasis. Clin Exp Metastasis 1988;6:91–102.

    PubMed  CAS  Google Scholar 

  28. Fidler IJ: Critical factors in the biology of human cancer metastasis. Cancer Res 1990;50:6130–6138.

    PubMed  CAS  Google Scholar 

  29. Horak E, Darling DL, Terin D: Analysis of organ-specific effects on metastatic tumor formation by studies in-vitro. J Natl Cancer Inst 1986; 76:913–922.

    PubMed  CAS  Google Scholar 

  30. Nicolson GL: differential growth properties of metastatic large cell lymphoma in target organ-conditioned medium. Exp Cell Res 1987; 168:272–277.

    Google Scholar 

  31. Sporn MB, Roberts AB: Peptide growth factors are multifunctional. Nature 1988;332:217–219.

    PubMed  CAS  Google Scholar 

  32. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986;46: 467–473.

    PubMed  CAS  Google Scholar 

  33. Folkman J, Klagsburn M: Angiogenic factors. Science 1987;235: 444–447.

    Google Scholar 

  34. Kamata N, Chida K, Rikimaru K, Horikoshi M, Enomoto S, Kuroki T: Growth inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res 1986;46:1648–1653.

    PubMed  CAS  Google Scholar 

  35. Schweigerer L, Neufeld G, Gospodarowicz D: Basic fibroblast growth factor as a growth inhibitor for cultured human tumor cells. J Clin Invest 1987;80:1516–1520.

    PubMed  CAS  Google Scholar 

  36. Braslawsky GR, Yaakubowicz M, Frensdorff A, Witz IP: Receptors for immune complexes on cells within a non-lymphoid murine tumor. J Immunol 1976;116:1571–1578.

    PubMed  CAS  Google Scholar 

  37. Braslawsky GR, Ran M, Witz IP: Tumor-bound immunoglobulins: The relationship between the in-vivo coating of tumor cells by potentially cytotoxic anti-tumor antibodies and the expression of complex receptors in-vivo. Int J Cancer 1976;18:116–121.

    PubMed  CAS  Google Scholar 

  38. Braslawsky GR, Serban D, Witz IP: Receptors for immune complexes on cells within a polyoma virus-induced murine sarcoma. Eur J Immunol 1976;6:579–583.

    PubMed  CAS  Google Scholar 

  39. Witz IP: Tumor-bound immunoglobulins. In situ expression of tumor immunity. Adv Cancer Res 1977;25:95–148.

    PubMed  CAS  Google Scholar 

  40. Ran M, Witz IP, Landes E, Brenner HJ, Izsak FCh: Immunoglobulin coating of human cancer cells. Correlation with clinical behaviour. Excerpta Med Int Congr Ser 1973;321: 244–249.

    Google Scholar 

  41. Ran M, Witz IP: Tumor-associated immunoglobulins: The elution of IgG2 from mouse tumors. Int J Cancer 1970;6:361–372.

    PubMed  CAS  Google Scholar 

  42. Ran M, Dux Z, Anavi R, Witz IP: Expression of Fcγ receptors on a subpopulation of non-lymphoid tumor cells and its enrichment. J Natl Cancer Inst 1984;73:437–446.

    PubMed  CAS  Google Scholar 

  43. Ran M, Katz B-Z, Kimchi N, Halachmi E, Teillaud J-L, Even J, Berko-Flint Y, Atlas E, Fridman WH, Witz IP: The in-vivo acquisition of FcγRII expression on polyoma virus transformed cells derived from tumors of long latency. Cancer Res 1991;51:612–618.

    PubMed  CAS  Google Scholar 

  44. Berko-Flint Y, Fridman WH, Grossman-Atlas E, Kimchi N, Langer-Ben Baruch A, Moss S, Teillaud J-L, Witz IP, Ran M: Some characteristics of high and low tumorigenicity variants of polyoma virus transformed cells. Mol Immunol 1990; 27:1219–1228.

    PubMed  CAS  Google Scholar 

  45. Tönder O, Thunold S: Receptors for immunoglobulin Fc in human malignant tissue. Scand J Immunol 1973;2:207–215.

    PubMed  Google Scholar 

  46. Tönder O, Morse PA Jr, Humphrey LJ: Similarities of Fc receptors in human malignant tissue and normal lymphoid tissue. J Immunol 1974; 113:1162–1169.

    PubMed  Google Scholar 

  47. Tönder O, Humphrey LJ, Morse PA Jr: Further observations on Fc receptors in human malignant tissue and normal lymphoid tissue. Cancer 1975;35:580–587.

    PubMed  Google Scholar 

  48. Matre R, Tönder O, Thunold S, Solhaug JH: Properties of Fc receptors in normal and malignant human tissue. Scand J Immunol 1976;5:361–368.

    PubMed  CAS  Google Scholar 

  49. Colnaghi MI, Regazzoni M, Boiocchi M, Galante E, Di Re F: Fc receptor-like structures on in-vitro cultured human ovarian tumor cells. Tumori 1978;64:587–596.

    PubMed  CAS  Google Scholar 

  50. Tönder O, Krishnan EC, Morse PA Jr, Jewell WR, Humphrey LJ: Lovalization of Fc receptors in human and rat malignant tissues. Acta Pathol Microbiol Scand 1978;86:173–178.

    Google Scholar 

  51. Wesenberg F: Fcγ receptors and IgG associated with human malignant tumours. Acta Pathol Microbiol Scand 1978;86:259–263.

    Google Scholar 

  52. Biran H, Mavligit Gm, Moake JL: Receptor sites for complement and for immune complexes on human nonhemopoietic tumor cells. Cancer 1979;44:131–135.

    PubMed  CAS  Google Scholar 

  53. Tönder O, Matre R: Localization of Fc receptors in human malignant tissue. Scand J Immunol 1979;10: 382–383.

    Google Scholar 

  54. Krishnan EC, Thomas JH, Jewell WR: Characterization of Fc receptors associated with breast carcinoma. J Surg Res 1979;26:64–68.

    PubMed  CAS  Google Scholar 

  55. Noltenius HW: Fc and complement receptors on malignant tumor cells. Cancer 1981;48:1761–1767.

    PubMed  CAS  Google Scholar 

  56. Svennevig J, Andersson TR: Cells bearing Fc receptors in human malignant solid tumours. Br J Cancer 1982;45:201–208.

    PubMed  CAS  Google Scholar 

  57. Forsgren A, Sjoquist J: Protein A fromS. aureus: Pseudoimmune reaction with human γ-globulin. J Immunol 1966;97:882–889.

    Google Scholar 

  58. Nilsson R, Myhre E, Kronvall G, Sjogren HO: Fractionation of rat IgG subclasses and screening for IgG Fc-binding to bacteria. Mol Immunol 1982;19:119–126.

    PubMed  CAS  Google Scholar 

  59. Lebrun L, Pillot J, Grangeot-Keros L, d’Azambuja S: An indirect immunofluorescence staining procedure for detection of human Fc receptors on streptococci. J Immunol Methods 1982;48:349–358.

    PubMed  CAS  Google Scholar 

  60. Forsgren A, Grubb AO: Many bacterial species bind human IgD. J Immunol 1979;122:1468–1472.

    PubMed  CAS  Google Scholar 

  61. Lindahl G, Akerstrom B, Vaerman J-P, Stenberg L: Characterization of ag IgA receptor from group B streptococci: Specificity for serum IgA. Eur J Immunol 1990;20:2241–2247.

    PubMed  CAS  Google Scholar 

  62. Para MF, Goldstein L, Spear PG: Similarities and differences in the Fc-binding glycoprotein (gE) of Herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J Virol 1982;41:137–144.

    PubMed  CAS  Google Scholar 

  63. Dowler KW, Veltri RW: In vitro neutralization of HSV-2: Inhibition by binding of normal IgG and purified Fc to virion Fc receptor (FcR). J Med Virol 1984;13:251–259.

    PubMed  CAS  Google Scholar 

  64. Torpie G, Capron A, Quaissi MA: Receptor for IgG (Fc) and human beta-2-microglobulin on S. mansoni schistosomula. Nature 1979;278: 447–450.

    Google Scholar 

  65. Tarleton RL, Kemp WM: Demonstration of IgG-Fc and C3 receptors on adultSchistosoma mansoni. J Immunol 1981;126:379–384.

    PubMed  CAS  Google Scholar 

  66. Ran M, Witz IP: FcR derived from without the immune system: A potential escape mechanism for cells propagating in a hostile immunological environment. Contr Gynecol Obstet 1985;14:83–89.

    CAS  Google Scholar 

  67. Witz IP, Ran M: Could Fc-Receptor facilitate the escape of immunogenic premalignant cells from host defence? A hypothesis. Ann Inst Pasteur 1985;136C:423–428.

    Google Scholar 

  68. Paraskevas F, Lee ST, Orr KB, Israels LG: A receptor for Fc on mouse B lymphocytes. J Immunol 1972;108:1319–1326.

    PubMed  CAS  Google Scholar 

  69. Cline MS, Sprent J, Warner NL, Harris AW: Receptors for immunoglobulin on B lymphocytes and cells of a cultured plasma-cell tumor. J Immunol 1972;108:1126–1131.

    PubMed  CAS  Google Scholar 

  70. Kerbel RS, Davies AJS: The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell 1974;3:105–112.

    PubMed  CAS  Google Scholar 

  71. Szymaniec S, James K: Studies on the Fc receptor bearing cells in a transplanted methylcholanthrene induced mouse fibrosarcoma. Br J Cancer 1976;33:36–50.

    PubMed  CAS  Google Scholar 

  72. Wood GW, Gollahon KA: Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell surface markers. J Natl Cancer Inst 1977;59:1081–1087.

    PubMed  CAS  Google Scholar 

  73. Turner DTL, Connolly CE, Isaacson P, Turnbull AR: Receptors for Fc and complement in human breast carcinoma. Clin Oncol 1978;4:87–92.

    PubMed  CAS  Google Scholar 

  74. Wood GW, Gillespie GY, Barth RL: Receptor sites for antigen-antibody complexes on cells derived from solid tumors: Detection by means of antibody sensitized sheep erythrocytes labeled with technetium-99m. J Immunol 1975;114:950–957.

    PubMed  CAS  Google Scholar 

  75. Chan KH, Yip TC, Ng WL, Ng MH: A shared antigenic determinant between human B lymphocytes and carcinomas. Int J Cancer 1985;36: 329–336.

    PubMed  CAS  Google Scholar 

  76. Klinken SP, Alexander WS, Adams JM: Hemopoietic lineage switch: v-raf oncogene converts E-myc transgenic B cells into macrophages. Cell 1988;53:857–867.

    PubMed  CAS  Google Scholar 

  77. Kerbel RS, Pross HF: Fc receptor-bearing cells as a reliable marker for quantitation of host lymphoreticular infiltration of progressively growing solid tumors. Int J Cancer 1976;18:432–438.

    PubMed  CAS  Google Scholar 

  78. Evans R: Macrophages in syngeneic animal tumors. Transplantation 1972;14:468–474.

    Article  PubMed  CAS  Google Scholar 

  79. Wood GL, Gillespie Y: Studies on the role of macrophages in regulation of growth and metastasis of murine chemically-induced tumors. Int J Cancer 1975;16:1022–1029.

    PubMed  CAS  Google Scholar 

  80. Haskill JS, Proctor WJ, Yamamura Y: Host responses within solid tumors. I. Monocyte effector cells within rat sarcoma. J Natl Cancer Inst 1975;54:387–392.

    PubMed  CAS  Google Scholar 

  81. Haskill JS, Yamamura Y, Radov L: Host responses within solid tumors: Non-thymus derived specific cytotoxic cells within a murine mammary adeno-carcinoma. Int J Cancer 1975;16:798–809.

    PubMed  CAS  Google Scholar 

  82. Tracey DE, Pross HF, Jondal M, Witz IP: Antibody-dependent cell mediated cytotoxic activity in syngeneic mouse ascites tumors. Int J Cancer 1975;16:870–880.

    PubMed  CAS  Google Scholar 

  83. Tötterman TH, Hayry P, Saksela E, Timonen T, Eklund B: Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II. Functional investigations of the infiltrating inflammatory cells. Eur J Immunol 1978;8: 872–875.

    PubMed  Google Scholar 

  84. Yoshida TO, Andersson B: Evidence for a receptor recognizing antigen complexed immunoglobulin on the surface of activated mouse thymus lymphocytes. Scand J Immunol 1972;1:401–408.

    PubMed  CAS  Google Scholar 

  85. Fridman WH, Goldstein P: Immunoglobulin binding factor present on and produced by thymus processed lymphocytes. Cell Immunol 1974; 11:442–455.

    PubMed  CAS  Google Scholar 

  86. Kerbel RS, Pross HF, Leibowitz A: Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors. Int J Cancer 1977;20:673–679.

    PubMed  CAS  Google Scholar 

  87. Milgrom F, Humphrey IJ, Tonder O, Yasuda J, Witebsky E: Antibody mediated hemadsorption by tumor tissues. Int Arch Allergy Appl Immunol 1968;33:478–492.

    PubMed  CAS  Google Scholar 

  88. Cohen D, Gurner BW, Coombs RRA: A phenomenon resembling opsonic adherance shown by disaggregated cells of the transmissible veneral tumor of the dog. Br J Exp Pathol 1971;52:447–451.

    Google Scholar 

  89. Ran M, Teillaud J-L, Fridman WH, Frenkel H, Halachmi E, Katz B, Gips M, Shlomo Y, Barzilay J, Witz IP: Increased expression of Fc receptor in cancer patients and tumor bearing mice. Mol Immunol 1988; 25:1159–1167.

    PubMed  CAS  Google Scholar 

  90. Hellstrom I, Hellstrom KE, Sjogren HO: Further studies on superinfection of polyoma-induced mouse tumors with polyoma virus. Virology 1962;16:282–300.

    PubMed  CAS  Google Scholar 

  91. Sjogren HO, Ringerts N: Histopathology and transplantability of polyoma-induced tumors in strain A/Sn and three coisogenic resistant (IR) substrains. J Natl Cancer Inst 1962;28:859–895.

    PubMed  CAS  Google Scholar 

  92. Witz IP, Lee N, Klein G: Serologically detectable specific and cross-reactive antigens on the membrane of a polyoma virus-induced murine tumor. Int J Cancer 1976;18:243–249.

    PubMed  CAS  Google Scholar 

  93. Klein G, Ehlin B, Witz IP: Serological detection of a polyoma tumor-associated membrane antigen. Int J Cancer 1979;23:683–690.

    PubMed  CAS  Google Scholar 

  94. Ran M, Klein G, Witz IP: Tumor-bound immunoglobulins. Evidence for the in-vivo coating of tumor cells by potentially cytotoxic antitumor antibodies. Int J Cancer 1976;17: 90–97.

    PubMed  CAS  Google Scholar 

  95. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979;150:580–596.

    PubMed  CAS  Google Scholar 

  96. Bonnerot C, Daeron M, Varin N, Amigorena S, Hogarth PM, Even J, Fridman WH: Methylation in the 5′ region of the murine βFcγR gene regulates the expression of FcγR receptor II. J Immunol 1988;141: 1026–1033.

    PubMed  CAS  Google Scholar 

  97. Nathan CF: Use of Lidocaine for detachment of adherent mononuclear phagocytes; in Adams DO, Edelson PJ, Koren H (eds): Methods for Studying Mononuclear Phagocytes. Academic Press, London, 1981, pp 221–230.

    Google Scholar 

  98. Ravetch JV, Luster AD, Weinshank R, Kochan J, Palovec A, Portnoy DA, Hulmess J, Parn Y-C, Unkeless J: Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 1986;234:718–725.

    PubMed  CAS  Google Scholar 

  99. Haugen A, Matre R: Fc receptors on fetal rat brain cells during neoplastic transformation in culture after exposure to ethylnitrosourea in vivo. Cancer Lett 1979;9:97–102.

    Google Scholar 

  100. Para MF, Baucke RB, Spear PG: Glycoprotein gE of Herpes simplex virus type 1: Effects of anti-gE on virion infectivity and on virus-induced Fc-binding receptors. J Virol 1982;41:129–136.

    PubMed  CAS  Google Scholar 

  101. Schirrmacher V, Jacobs W: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc receptors on metastatic tumor cell variants. J Supramol Struct 1979;11:105–111.

    PubMed  CAS  Google Scholar 

  102. Benke R, Lang E, Komitowski D, Muto S, Schirrmacher V: Changes in tumor cell adhesiveness affecting speed of dissemination and mode of metastatic growth. Invasion Metastasis 1988;8:159–176.

    PubMed  CAS  Google Scholar 

  103. Altevogt P, Heckl-Oestreicher G, Lang E, Kohl U, Kratzin H, Schirrmacher V: Murine Fc receptor proteins: identification of a previously unrecognized molecule with a monoclonal antibody (12–15). Eur J Immunol 1988;18:677–683.

    PubMed  CAS  Google Scholar 

  104. Klein G: Immune surveillance: A powerful mechanism with a limited range. Natl Cancer Inst Monogr 1976;44:109–113.

    PubMed  CAS  Google Scholar 

  105. Witz IP, Meyer G: Membrane antigen associated with infection, transformation and tumorigenesis by polyoma virus. Cancer Immunol Immunother 1984;17:147–153.

    PubMed  CAS  Google Scholar 

  106. Klein G, Klein E: Evolution of tumours and the impact of molecular oncology. Nature (Lond) 1985; 315:190–195.

    CAS  Google Scholar 

  107. Fridman WH, Teillaud J-L, Amigorena S, Daëron M, Blank U, Neauport-Sautes C: The isotypic circuit: Immunoglobulins, Fc receptors and immunoglobulin-binding factors. Int Rev Immunol 1987;2:221–240

    PubMed  CAS  Google Scholar 

  108. Daëron M, Sautes C, Bonnerot C, Blank U, Varin N, Even J, Hogarth PM, Fridman WH: Murine type II Fcγ receptors and IgG-binding factors; in Ishizaka K, Lachman PJ, Lerner R, Waksman BH (eds): Chemical Immunology. Basel, Karger, 1989, vol 47, pp 21–78.

    Google Scholar 

  109. Theofilopoulos AN, Dixon FJ: Immune complexes associated with neoplasia; in Herberman B, McIntire KR (eds): Immunodiagnosis of Cancer. New York: Dekker, 1979, pp 896–937.

    Google Scholar 

  110. Khayat D, Dux Z, Anavi R, Shlomo Y, Witz IP, Ran M: Circulating cellfree Fcγ2b/γ1 receptor in normal mouse serum: Its detection and specificity. J Immunol 1984; 132:2496–2501.

    PubMed  CAS  Google Scholar 

  111. Billaud M, Busson P, Huang D, Mueller-Lantzch N, Rousselet G, Pavlish O, Wakasugi H, Seigneurin JM, Tursz T, Lenoir M: Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2. J Virol 1989;63:4121–4128.

    PubMed  CAS  Google Scholar 

  112. Ilfed D, Barzilay J, Dux Z, Ran M: Correlation of Fcγ receptors on peripheral blood mononuclear cells and survival in patients with metastatic breast cancer. Breast Cancer Res Treat 1986;7:181–186.

    Google Scholar 

  113. Guy GR, Gordon J: Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth. Proc Natl Acad Sci USA 1987;84:6239–6243.

    PubMed  CAS  Google Scholar 

  114. Raz A, Lotan R: Endogenous galactoside binding lectins: A new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 1987;6: 433–452.

    PubMed  CAS  Google Scholar 

  115. Raz A, Pazerini G, Carmi P: Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein. Cancer Res 1989;49:3489–3493.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, 69978, Tel Aviv, Israel

    Isaac P. Witz & Maya Ran

  2. Moise and Frida Eskenasy Institute for Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

    Isaac P. Witz & Maya Ran

Authors
  1. Isaac P. Witz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maya Ran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witz, I.P., Ran, M. FcR may function as a progression factor of nonlymphoid tumors. Immunol Res 11, 283–295 (1992). https://doi.org/10.1007/BF02919134

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02919134

Key Words

Search

Navigation